LBCA's Mission: to raise awareness of ILC and its unique characteristics; to be the go-to source for information on ILC and clinical trials, and to foster partnerships among patients, scientists, clinicians, and breast cancer organizations around the world to promote more ILC research.
What's new
ILC Research
Education & Advocacy
My ILC Story
Lobular Breast Cancer Videos
Watch our videos on research and advocacy
Hear About Latest LBCA Local Advocacy Team Activities
LBCA Lobular Breast Cancer Chat: Biomarkers as Tools in ILC
Interview with New SAB Board Member, Dr. Rebecca Shatsky
LBCA Promotes Issues on ILC and Imaging in President’s Cancer Moonshot Program
LBCA Vidoe Takes In-Depth Look at Lobular Breast Cancer
Professional Golfer Angela Stanford Educates People About ILC
What Is Invasive Lobular Carcinoma?
Invasive lobular carcinoma (ILC), also known as lobular breast cancer, is 15% of all breast cancer diagnosis and the sixth most frequently diagnosed cancer of women in the US with over 46,000 new patients diagnosed each year.Â
Research indicates that ILC is a unique histological subtype of breast cancer with distinct biological and behavioral differences.
It’s time to advance research to better understand ILC and its differences and refine treatments for patients with lobular breast disease.
For Patients
Access the extensive resources we have compiled for individuals with invasive lobular carcinoma (ILC) and their loved ones.
Facebook Groups
LBCA does not administer, moderate or review the content posted in these social media groups or the hotlines.
ILC Clinical Trials
Help advance the understanding of ILC by participating in clinical trials.
Patients with invasive lobular carcinoma (ILC) can advance understanding of the disease by joining clinical trials. Few trials focus solely on ILC due to its lower incidence (10-15% of all breast cancers), but participation is crucial.
 Increased research could help improve detection, treatment, prevention of metastasis, and ultimately, develop a cure for people with ILC.
